150-300 mg PO qDay
Primary Fibromyalgia Syndrome
100 mg PO TID for up to 1 month
Tetrahydrobiopterin Deficiency (Orphan)
Orphan indication sponsor
- Watson Laboratories, Inc; 311 Bonnie Circle, P.O. Box 1900; Corona, CA 91718-1900
Anxiety, cerebellar ataxia, depression, fibromyalgia syndrome (primary), headaches (migraine/tension), myoclonus (intention/post-anoxic), Ramsey-Hunt syndrome, seizure disorder (adjunctive therapy), sleep disorders
Possibly effective for depression and fibromyalgia
Serious - Use Alternative
Significant - Monitor Closely
Anorexia, diarrhea, eosinophilia myalgia syndrome, eosinophilia (asymptomatic), flatulence, heartburn, nausea/vomiting, stomach pain
Down syndrome, peptic ulcers, platelet disorders, renal disease
Pregnancy & Lactation
Pregnancy Category: N/A
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
5-hydroxytryptophan is precursor of serotonin (5-hydroxytryptamine); boosts serotonin levels in CNS